drugset / Trial / NCT07158437
Phase 1 Study of SL-325 in Healthy Volunteers
RandomizedSequentialDouble-blindTreatment
Summary
This first-in-human study is a randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose study of SL-325 in healthy volunteers.
Timeline
- Start
- 2025-09-18
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SL-325 | Unknown | — | — |
Indications
No indication recorded.